Pfizer Inc. Chief Executive Albert Bourla said on January 22 that an annual COVID-19 vaccine would be preferable to more frequent booster shots in fighting the coronavirus pandemic.
The U.S. Food and Drug Administration approved AbbVie’s Skyrizi (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA), a systemic inflammatory disease that affects the skin and joints and impacts 30 percent of patients with psoriasis.
Three U.S. studies show that a third dose of an mRNA vaccine is key to fighting the Omicron coronavirus variant, providing 90% protection against hospitalization due to COVID-19, the U.S. Centers for Disease Control and Prevention (CDC) said on January 21.
The U.S. FDA on January 21 expanded the health regulator’s approval for the use of Gilead Sciences’ antiviral drug remdesivir to treat non-hospitalized patients 12 years and older for the treatment of mild-to-moderate COVID-19 disease with high risk of hospitalization.
In very young children, the Omicron variant of the coronavirus causes less severe disease than the Delta variant, according to a new study. In other research, new findings add to evidence that people with a certain version of a gene are less likely to develop severe COVID-19.
Sorrento Therapeutics announced that the company’s COVID-19 treatment Covishield (STI-9167) shows significant progress in neutralizing Omicron and Omicron variants of SARS-COV-2.
GlaxoSmithKline and U.S. partner Vir Biotechnology will boost production of their antibody-based COVID-19 treatment by adding a second manufacturing plant to help meet soaring demand in the United States.
New coronavirus cases are falling in parts of the United States hit hardest by the fast-spreading Omicron variant, according to a Reuters analysis of public health data, offering an early indication the virus might once again be in retreat.
Researchers have been working to develop approaches to curing Type 1 diabetes by transplanting healthy islet cells into the pancreas. Investigators at Northwestern University have developed a technique to make the immunomodulation effect of immunosuppressive drugs more effective.
The Omicron variant, which is spreading far faster than previous versions of the coronavirus, is not likely to help countries achieve so-called herd immunity against COVID-19 – in which enough people become immune to the virus that it can no longer spread – leading disease experts say.
